Portugal vs Small Island Developing States (SIDS): Proportion of the target population … measles-containing-vaccine
Portugal
96.0%
in 2024
Small Island Developing States (SIDS)
63.0%
in 2024
Portugal rank
28th
Small Island Developing States (SIDS) rank
29th
Proportion of the target population … measles-containing-vaccine over time
- Portugal
- Small Island Developing States (SIDS)
How they compare
Portugal currently reports 96.0% against 63.0% in Small Island Developing States (SIDS), a difference of 33.0%.
That makes Portugal's figure about 1.5 times Small Island Developing States (SIDS)'s.
Across all 25 years both countries report, Portugal has been ahead every year.
Portugal ranks 28th and Small Island Developing States (SIDS) ranks 29th of 195 countries.
Portugal has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Portugal | Small Island Developing States (SIDS) | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 78.6% | 19.6% | 59.0% | Portugal |
| 2010s | 95.6% | 31.6% | 64.0% | Portugal |
| 2020s | 95.4% | 56.8% | 38.6% | Portugal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received, Portugal or Small Island Developing States (SIDS)?
- Portugal, at 96.0% against 63.0% in Small Island Developing States (SIDS) as of 2024.
- What is the difference in proportion of the target population who received between Portugal and Small Island Developing States (SIDS)?
- 33.0%, with Portugal ahead.
- How many years of comparable data are there for Portugal and Small Island Developing States (SIDS)?
- 25 years are reported by both, from 2000 to 2024.
- How do Portugal and Small Island Developing States (SIDS) rank globally for proportion of the target population who received?
- Portugal ranks 28th and Small Island Developing States (SIDS) ranks 29th of 195 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received measles-containing-vaccine second-dose (MCV2) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.